On Friday, Piper Sandler reaffirmed its Overweight rating on shares of Turnstone Biologics (NASDAQ:TSBX), maintaining a price target of $20.00. Turnstone Biologics has recently announced its first-quarter earnings for 2024 and provided an update on its pipeline. The company is on schedule to present a clinical update on its leading program, TIDAL-01, anticipated to coincide with its second-quarter 2024 earnings report.
The forthcoming clinical update will particularly concentrate on a group of late-stage colorectal cancer (CRC) patients. Current standard treatments have limited effectiveness in this area, and Turnstone Biologics aims to demonstrate the potential of its therapy where other tumor-infiltrating lymphocyte (TIL) therapies have shown minimal success. The company plans to focus its efforts on CRC, as well as head and neck and uveal melanoma, which are seen as key areas for establishing its treatment's distinctiveness.
Turnstone Biologics reported having cash reserves of $78 million, which is expected to sustain the company's operations into the second half of 2025. This financial position is deemed adequate for Turnstone Biologics to achieve initial clinical proof-of-concept for its tumor-selective TIL platform. The TIDAL-01 program update is particularly significant as it represents the company's commitment to advancing its lead program and potentially addressing unmet needs in the treatment of CRC and other cancers.
The company's strategic focus on CRC, head and neck, and uveal melanoma indicates its intent to differentiate its treatment in the oncology market. With the financial runway to support its operations and clinical trials, Turnstone Biologics is poised to continue its development efforts in pursuit of establishing a new standard of care for patients with these forms of cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.